Autologous Tumor-Infiltrating Lymphocyte Mono-Therapy Can Rapidly Shrank Tumor in Asian Patient with Stage III/IV Cervical Cancer: Two Cases Report.
Fenge LiYupeng WangJin YanHuancheng WuXueming DuWeihong FengXiaoqing ZhangYongming XueHuaqing WangWenxin LiuPublished in: International journal of women's health (2024)
These results suggest that TILs mono-therapy can be a promising treatment strategy for Asian patients with late-stage metastatic cervical cancer even with severe myelosuppression. TILs infusion can induce persistence and a long-term systematic immune response that reversed peripheral CD4+T and CD8+T percentages implying that TILs infusion increased cytotic T cell responses, which is consistent with clinical responses in these patients. Trial registration number: NCT05366478.
Keyphrases
- immune response
- end stage renal disease
- low dose
- squamous cell carcinoma
- ejection fraction
- newly diagnosed
- chronic kidney disease
- small cell lung cancer
- prognostic factors
- study protocol
- peritoneal dialysis
- cell therapy
- bone marrow
- early onset
- case report
- phase iii
- nk cells
- toll like receptor
- replacement therapy
- combination therapy
- platelet rich plasma
- patient reported